PRTK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRTK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Paratek Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Paratek Pharmaceuticals's Piotroski F-Score or its related term are showing as below:
During the past 13 years, the highest Piotroski F-Score of Paratek Pharmaceuticals was 5. The lowest was 1. And the median was 3.
The historical data trend for Paratek Pharmaceuticals's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paratek Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Piotroski F-Score | Get a 7-Day Free Trial | 3.00 | 1.00 | 3.00 | 4.00 | 2.00 |
Paratek Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Piotroski F-Score | Get a 7-Day Free Trial | 3.00 | 3.00 | 2.00 | 3.00 | 5.00 |
For the Biotechnology subindustry, Paratek Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Paratek Pharmaceuticals's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun23) TTM: | Last Year (Jun22) TTM: |
Net Income was -20.88 + -7.157 + -20.143 + -14.553 = $-62.7 Mil. Cash Flow from Operations was -12.419 + -20.113 + 11.09 + -1.776 = $-23.2 Mil. Revenue was 27.845 + 72.627 + 29.208 + 38.062 = $167.7 Mil. Gross Profit was 23.473 + 62.315 + 22.964 + 33.694 = $142.4 Mil. Average Total Assets from the begining of this year (Jun22) to the end of this year (Jun23) was (163.695 + 157.321 + 172.538 + 150.828 + 145.792) / 5 = $158.0348 Mil. Total Assets at the begining of this year (Jun22) was $163.7 Mil. Long-Term Debt & Capital Lease Obligation was $95.7 Mil. Total Current Assets was $105.2 Mil. Total Current Liabilities was $202.6 Mil. |
Net Income was -18.202 + -32.253 + -17.91 + -17.619 = $-86.0 Mil. Revenue was 21.436 + 29.298 + 22.762 + 27.555 = $101.1 Mil. Gross Profit was 17.147 + 24.58 + 19.268 + 22.677 = $83.7 Mil. Average Total Assets from the begining of last year (Jun21) to the end of last year (Jun22) was (179.588 + 182.348 + 183.869 + 170.157 + 163.695) / 5 = $175.9314 Mil. Total Assets at the begining of last year (Jun21) was $179.6 Mil. Long-Term Debt & Capital Lease Obligation was $258.0 Mil. Total Current Assets was $127.8 Mil. Total Current Liabilities was $30.1 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Paratek Pharmaceuticals's current Net Income (TTM) was -62.7.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Paratek Pharmaceuticals's current Cash Flow from Operations (TTM) was -23.2.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Jun22) |
= | -62.733 | / | 163.695 | |
= | -0.38323101 |
ROA (Last Year) | = | Net Income | / | Total Assets (Jun21) |
= | -85.984 | / | 179.588 | |
= | -0.47878477 |
Paratek Pharmaceuticals's return on assets of this year was -0.38323101. Paratek Pharmaceuticals's return on assets of last year was -0.47878477.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Paratek Pharmaceuticals's current Net Income (TTM) was -62.7. Paratek Pharmaceuticals's current Cash Flow from Operations (TTM) was -23.2.
==> -23.2 > -62.7 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Jun23) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Jun22 to Jun23 |
= | 95.714 | / | 158.0348 | |
= | 0.60565141 |
Gearing (Last Year: Jun22) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Jun21 to Jun22 |
= | 258.007 | / | 175.9314 | |
= | 1.46652047 |
Paratek Pharmaceuticals's gearing of this year was 0.60565141. Paratek Pharmaceuticals's gearing of last year was 1.46652047.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Jun23) | = | Total Current Assets | / | Total Current Liabilities |
= | 105.227 | / | 202.619 | |
= | 0.51933432 |
Current Ratio (Last Year: Jun22) | = | Total Current Assets | / | Total Current Liabilities |
= | 127.768 | / | 30.1 | |
= | 4.24478405 |
Paratek Pharmaceuticals's current ratio of this year was 0.51933432. Paratek Pharmaceuticals's current ratio of last year was 4.24478405.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Paratek Pharmaceuticals's number of shares in issue this year was 57.282. Paratek Pharmaceuticals's number of shares in issue last year was 53.023.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 142.446 | / | 167.742 | |
= | 0.84919698 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 83.672 | / | 101.051 | |
= | 0.82801754 |
Paratek Pharmaceuticals's gross margin of this year was 0.84919698. Paratek Pharmaceuticals's gross margin of last year was 0.82801754.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Jun22) |
= | 167.742 | / | 163.695 | |
= | 1.02472281 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Jun21) |
= | 101.051 | / | 179.588 | |
= | 0.56268236 |
Paratek Pharmaceuticals's asset turnover of this year was 1.02472281. Paratek Pharmaceuticals's asset turnover of last year was 0.56268236.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 0 | + | 0 | + | 1 | + | 1 | + | 1 | + | 0 | + | 0 | + | 1 | + | 1 | |
= | 5 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Paratek Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Paratek Pharmaceuticals (NAS:PRTK) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Minnie Baylor-henry | director | C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803 |
Kristine Peterson | director | AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355 |
Timothy R Franson | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Jeffrey Stein | director | 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Thomas John Dietz | director | C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804 |
Evan Loh | director, officer: CEO | 75 KNEELAND STREET, BOSTON MA 02111 |
William M. Haskel | officer: CLO, General Counsel & Sec. | ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073 |
Adam Woodrow | officer: President & Chief Commercial | C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111 |
Randall B. Brenner | officer: Chief Development & Regulatory | C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116 |
Robert S Radie | director | 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355 |
Rolf K Hoffmann | director | LORBEERWEG 7, WEGGIS V8 CH-6353 |
Michael Bigham | director, officer: Exec. Chairman of the Board | 890 WINTER STREET, WALTHAM MA 02451 |
James D Dondero | 10 percent owner | 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201 |
Douglas W. Pagan | officer: Chief Financial Officer | 75 KNEELAND STREET, BOSTON MA 02111 |
Omega Fund Iv, L.p. | 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
From GuruFocus
By PRNewswire • 08-23-2023
By sperokesalga sperokesalga • 06-12-2023
By PRNewswire • 06-27-2023
By PRNewswire • 08-28-2023
By Marketwired • 08-08-2023
By Marketwired • 07-18-2023
By Business Wire • 08-09-2023
By Marketwired • 06-27-2023
By Marketwired • 09-18-2023
By Marketwired • 10-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.